Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial – The Lancet

by

  1. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial The Lancet
  2. First Vaccine For Chikungunya—An Emerging Mosquito-Borne Threat—Nears After Promising Trial Results Forbes
  3. Valneva Reports Strong Phase III Chikungunya Vaccine Data After Merck’s Exit from Race BioSpace
  4. Positive results for potential first chikungunya vaccine – Wed, June 14 2023 The Jakarta Post
  5. Vaccine Candidate for Chikungunya Virus Safe and Effective Medpage Today
  6. View Full Coverage on Google News

Read original article here

Leave a Comment